The Medicines and Healthcare products Regulatory Agency (MHRA) has approved, Thursday, a four-dose version of the diabetes and weight management medicine Mounjaro (tirzepatide).
Eli Lilly And Co’s (NYSE:LLY) Mounjaro will be branded as Mounjaro KwikPen in the U.K.
In September, the U.K.’s National Institute for Health and Care Excellence (NICE) endorsed Mounjaro, indicating it as a viable option for patients grappling with poorly controlled type 2 diabetes.
The development occurred against the backdrop of national shortages of Novo Nordisk A/S’s (NYSE:NVO) Ozempic, a medication within the same drug class as Mounjaro and approved in